{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:31:22Z","timestamp":1791919882953,"version":"4.3.4"},"reference-count":303,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.prp.2024.155401","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:27:01Z","timestamp":1718666821000},"page":"155401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A comprehensive review of the PTEN\/PI3K\/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets"],"prefix":"10.1016","volume":"260","author":[{"given":"Mina","family":"Alimohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payman","family":"Rahimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Khorrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Bonyadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Daneshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Raesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh Ramezani","family":"Farani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Dehkhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Taheriazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155401_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.prp.2024.155401_bib2","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1038\/sj.onc.1206718","article-title":"Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway","volume":"22","author":"Zhang","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2024.155401_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Elsevier","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib4","article-title":"Multiple myeloma: focus on international epidemiology literature","volume":"27","author":"Veres","year":"2022","journal-title":"Acta Med. Transilv."},{"key":"10.1016\/j.prp.2024.155401_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of myeloma therapy","author":"Rajkumar","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.prp.2024.155401_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.prp.2024.155401_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/ijms23031649","article-title":"Multiple myeloma: Challenges encountered and future options for better treatment","volume":"23","author":"Das","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2024.155401_bib9","first-page":"578","volume":"vol. 92","author":"Dingli","year":"2017"},{"key":"10.1016\/j.prp.2024.155401_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.prp.2024.155401_bib11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1568009617666170214102301","article-title":"Multiple myeloma and the immune microenvironment","volume":"17","author":"Kawano","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.prp.2024.155401_bib12","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.18632\/oncotarget.24614","article-title":"Mouse models of multiple myeloma: technologic platforms and perspectives","volume":"9","author":"Rossi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","author":"Lonial","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.prp.2024.155401_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.prp.2024.155401_bib15","first-page":"95","article-title":"Detection of chromosome 13 (13q14) deletion among Sudanese patients with multiple myeloma using a molecular genetics fluorescent in situ hybridization technique (FISH)","volume":"37","author":"Dowd","year":"2015","journal-title":"Malays. J. Pathol."},{"key":"10.1016\/j.prp.2024.155401_bib16","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.prp.2024.155401_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.prp.2024.155401_bib18","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1182\/blood.V128.22.5634.5634","article-title":"Correlation between prognosis and morphological abnormalities in multiple myeloma","volume":"128","author":"Iida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155401_bib19","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10.1016\/j.prp.2024.155401_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-020-06870-w","article-title":"Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry","volume":"20","author":"Firsova","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2024.155401_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"39","key":"10.1016\/j.prp.2024.155401_bib26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","author":"Mina","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.prp.2024.155401_bib27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","article-title":"The pharmacologic management of multiple myeloma in older adults","volume":"20","author":"Dempsey","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.prp.2024.155401_bib28","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib29","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.3747\/co.20.1252","article-title":"Lenalidomide in multiple myeloma-a practice guideline","volume":"20","author":"Chen","year":"2013","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib30","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"haematologica"},{"key":"10.1016\/j.prp.2024.155401_bib31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2141.2009.07976.x","article-title":"The potential role of epigenetic therapy in multiple myeloma","volume":"148","author":"Smith","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.6401","article-title":"Cell-based gene therapy is new option for multiple myeloma","volume":"325","author":"Voelker","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.prp.2024.155401_bib33","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.3390\/ijms22073587","article-title":"Immunological prognostic factors in multiple myeloma","volume":"22","author":"B\u0119bnowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.prp.2024.155401_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.13506","article-title":"Global hypomethylation in myeloma is associated with poor prognosis","volume":"172","author":"Sive","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.prp.2024.155401_bib37","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.18632\/oncotarget.6843","article-title":"Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target","volume":"7","author":"Agarwal","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/jcp.2006.036715","article-title":"Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"60","author":"Chim","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155401_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12185-009-0459-2","article-title":"Methylation status of nine tumor suppressor genes in multiple myeloma","volume":"91","author":"Braggio","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib40","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.leu.2403434","article-title":"DNA methylation changes in multiple myeloma","volume":"18","author":"Galm","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib41","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/sj.leu.2404939","article-title":"Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma","volume":"21","author":"Chim","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib42","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib43","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41388-020-01590-8","article-title":"Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma","volume":"40","author":"Xu","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2024.155401_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.semcancer.2017.09.007","article-title":"Elsevier","volume":"51","author":"Alzrigat","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2024.155401_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41375-018-0300-0","article-title":"MMSET I acts as an oncoprotein and regulates GLO1 expression in t (4; 14) multiple myeloma cells","volume":"33","author":"Xie","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41420-020-00400-0","article-title":"Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis","volume":"7","author":"Ishiguro","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.prp.2024.155401_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100872","article-title":"Decoding DNA methylation in epigenetics of multiple myeloma","volume":"51","author":"Yang","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.prp.2024.155401_bib48","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.18632\/oncotarget.13773","article-title":"Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells","volume":"8","author":"Zeng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib49","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-dependent tumors to proteasome inhibitioncombined inhibition of PRC2 and proteasome in cancer","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149526","article-title":"Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t (4; 14) translocation","volume":"132","author":"Wang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.prp.2024.155401_bib51","first-page":"1234","article-title":"Effect of quercetin on proliferation and apoptosis of multiple myeloma cells and its related mechanism","volume":"28","author":"Xu","year":"2020","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"10.1016\/j.prp.2024.155401_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.18632\/oncotarget.820","article-title":"In vitro and in vivo anti-tumor activity of miR-221\/222 inhibitors in multiple myeloma","volume":"4","author":"Di Martino","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib53","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/cells12071030","article-title":"Exosomal miRNAs in the tumor microenvironment of multiple myeloma","volume":"12","author":"Alipoor","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155401_bib54","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/jcp.31053","article-title":"The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets","volume":"238","author":"Liu","year":"2023","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.prp.2024.155401_bib55","article-title":"Oridonin improves the sensitivity of multiple myeloma cells to bortezomib through the PTEN\/PI3K\/Akt pathway","volume":"18","author":"Wu","year":"2020","journal-title":"Curr. Top. Nutraceutical Res."},{"key":"10.1016\/j.prp.2024.155401_bib56","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3390\/cells9092038","article-title":"Nuclear Heparanase regulates chromatin remodeling, gene expression and PTEN tumor suppressor function","volume":"9","author":"Amin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155401_bib57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170264","article-title":"The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity","volume":"13","author":"Salemme","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib59","first-page":"645","article-title":"Circular RNAs: novel actors of Wnt signaling pathway in lung cancer progression","volume":"22","author":"Alimohammadi","year":"2023","journal-title":"EXCLI J."},{"key":"10.1016\/j.prp.2024.155401_bib60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.prp.2024.155401_bib61","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.3390\/cancers12102996","article-title":"Epigenetic aberrations in multiple myeloma","volume":"12","author":"Caprio","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib62","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","article-title":"Role of DNA methylation in the resistance to therapy in solid tumors","volume":"10","author":"Romero-Garcia","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib63","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2217\/epi-2022-0143","article-title":"DNA methylation changes and inflammaging in aging-associated diseases","volume":"14","author":"Alimohammadi","year":"2022","journal-title":"Epigenomics"},{"key":"10.1016\/j.prp.2024.155401_bib64","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/genes11111336","article-title":"DNMTs and impact of CpG content, transcription factors, consensus motifs, lncRNAs, and histone marks on DNA methylation","volume":"11","author":"Loaeza-Loaeza","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.prp.2024.155401_bib65","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1007\/s11033-021-06813-z","article-title":"What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma?","volume":"48","author":"Pehlivan","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib66","article-title":"Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2024.155401_bib67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41420-018-0063-4","article-title":"Cordycepin induces apoptosis of human ovarian cancer cells by inhibiting CCL5-mediated Akt\/NF-\u03baB signaling pathway","volume":"4","author":"Cui","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.prp.2024.155401_bib68","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2021.279517","article-title":"Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition","volume":"107","author":"Cuenca","year":"2022","journal-title":"haematologica"},{"key":"10.1016\/j.prp.2024.155401_bib69","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1038\/sj.onc.1210097","article-title":"The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1","volume":"26","author":"Cavarretta","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2024.155401_bib70","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/1042819031000068052","article-title":"Role of Apo2L\/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma","volume":"44","author":"Chen","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.prp.2024.155401_bib71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41419-020-2505-1","article-title":"Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes","volume":"11","author":"Seiller","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prp.2024.155401_bib72","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2024.155401_bib73","series-title":"Handbook of Cancer and Immunology","first-page":"1","author":"Tahmasebi","year":"2022"},{"key":"10.1016\/j.prp.2024.155401_bib74","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.3390\/ijms21186723","article-title":"Pathogenic mechanisms of myeloma bone disease and possible roles for NRF2","volume":"21","author":"Yen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2024.155401_bib75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/etm.2021.10137","article-title":"HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-\u03baB pathway","volume":"22","author":"Ning","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.prp.2024.155401_bib76","first-page":"16","article-title":"Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma","volume":"13","author":"Fuchs","year":"2013","journal-title":"Cardiovasc. Haematol. Disord. -Drug Targets (Former. Curr. Drug Targets-Cardiovasc. Hematol. Disord.)"},{"key":"10.1016\/j.prp.2024.155401_bib77","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1007\/s00018-021-03756-3","article-title":"Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma","volume":"78","author":"Xiong","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.prp.2024.155401_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.889954","article-title":"Autophagy and the bone marrow microenvironment: a review of protective factors in the development and maintenance of multiple myeloma","volume":"13","author":"Hamedi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155401_bib79","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4161\/auto.29264","article-title":"Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma","volume":"10","author":"Vogl","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.prp.2024.155401_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.08.019","article-title":"Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo","volume":"382","author":"Jarauta","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155401_bib81","first-page":"1","article-title":"Exploiting autophagy in multiple myeloma","volume":"5","author":"M","year":"2019","journal-title":"J. Cancer Metastas\u00a0Treat."},{"key":"10.1016\/j.prp.2024.155401_bib82","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.2174\/0929867321666140414100831","article-title":"IL-6 activated JAK\/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma","volume":"21","author":"Kolosenko","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2024.155401_bib83","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90\u03b1 and \u03b2 in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155401_bib84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3324\/haematol.2012.066175","article-title":"The PI3K\/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma","volume":"98","author":"Chatterjee","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2024.155401_bib85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2021.12.003","article-title":"Regulation of the tumor suppressor PTEN in triple-negative breast cancer","volume":"527","author":"Chai","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155401_bib86","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib87","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/ijms23031353","article-title":"Wnt and PI3K\/Akt\/mTOR survival pathways as therapeutic targets in glioblastoma","volume":"23","author":"Barzegar Behrooz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib88","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cbin.11894","article-title":"MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K\/AKT\/mTOR axis","volume":"46","author":"Kai","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.prp.2024.155401_bib89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng0497-356","article-title":"Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers","volume":"15","author":"Steck","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.prp.2024.155401_bib90","first-page":"1","article-title":"Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes","author":"Berndt","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104533","article-title":"Catch them if you are aware: PTEN postzygotic mosaicism in clinically suspicious patients with PTEN Hamartoma Tumour Syndrome and literature review","author":"Hendricks","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.prp.2024.155401_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2022.101792","article-title":"Gastrointestinal manifestations in PTEN hamartoma tumor syndrome","author":"D'Ermo","year":"2022","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.prp.2024.155401_bib93","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/diagnostics12081940","article-title":"Synchronous\/metachronous multiple primary malignancies: review of associated risk factors","volume":"12","author":"Pan","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2024.155401_bib94","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41598-023-31759-6","article-title":"Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome","volume":"13","author":"Vidotto","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103796","article-title":"Pten haploinsufficiency causes desynchronized growth of brain areas involved in sensory processing","volume":"25","author":"Clipperton-Allen","year":"2022","journal-title":"Iscience"},{"key":"10.1016\/j.prp.2024.155401_bib96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cancergen.2022.02.008","article-title":"PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas","author":"Jones","year":"2022","journal-title":"Cancer Genet. 264"},{"key":"10.1016\/j.prp.2024.155401_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.gendis.2022.12.015","article-title":"Synthetic lethal approaches to target cancers with loss of PTEN function","author":"Ertay","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.prp.2024.155401_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11396","article-title":"Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients","volume":"8","author":"Giannoni-Luza","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.prp.2024.155401_bib99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.reprotox.2022.08.008","article-title":"GRP78 plays a key role in sperm function via the PI3K\/PDK1\/AKT pathway","volume":"113","author":"Lee","year":"2022","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.prp.2024.155401_bib100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bbrc.2021.11.102","article-title":"A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells","volume":"587","author":"Kawano","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prp.2024.155401_bib101","first-page":"6","article-title":"PTEN gene and AKT\/mTOR pathway in gynecological cancers and cancer immune escape","volume":"1","author":"Zeng","year":"2022","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib102","first-page":"1177","article-title":"PI3K\/Akt\/mTOR signaling pathway: role in esophageal squamous cell carcinoma, regulatory mechanisms and opportunities for targeted therapy","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib103","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/16078454.2022.2117126","article-title":"Formosanin C induces autophagy-mediated apoptosis in multiple myeloma cells through the PI3K\/AKT\/mTOR signaling pathway","volume":"27","author":"Chen","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.prp.2024.155401_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1224151","article-title":"Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives","volume":"14","author":"Mafi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2024.155401_bib105","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.3390\/cancers14153666","article-title":"PTEN dual lipid-and protein-phosphatase function in tumor progression","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/antiox12010120","article-title":"The role of oxidative inactivation of phosphatase PTEN and TCPTP in fatty liver disease","volume":"12","author":"Nguyen Huu","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.prp.2024.155401_bib107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni.3311","article-title":"The tumor suppressor PTEN has a critical role in antiviral innate immunity","volume":"17","author":"Li","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2024.155401_bib108","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2024.155401_bib109","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.3390\/ijms21155337","article-title":"PTEN function at the interface between cancer and tumor microenvironment: implications for response to immunotherapy","volume":"21","author":"Conciatori","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ni.3076","article-title":"Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses","volume":"16","author":"Shrestha","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2024.155401_bib111","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.4049\/jimmunol.1302167","article-title":"Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses","volume":"193","author":"Sahin","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2024.155401_bib112","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1007\/s11033-022-07246-y","article-title":"Roles of PTEN inactivation and PD-1\/PD-L1 activation in esophageal squamous cell carcinoma","volume":"49","author":"Qiu","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114204","article-title":"Progress in targeting PTEN\/PI3K\/Akt axis in glioblastoma therapy: revisiting molecular interactions","volume":"158","author":"Hashemi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2024.155401_bib114","series-title":"Seminars in Oncology","author":"Bolomsky","year":"2022"},{"key":"10.1016\/j.prp.2024.155401_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2022.13226","article-title":"PI3K\/Akt\/YAP signaling promotes migration and invasion of DLD\u20111 colorectal cancer cells","volume":"23","author":"Takeda","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2024.155401_bib116","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7686728","article-title":"BAP31 promotes proliferation, invasion, and metastasis of liver cancer cells via activating PI3K\/AKT pathway","volume":"2022","author":"Sun","year":"2022","journal-title":"J. Healthc. Eng."},{"key":"10.1016\/j.prp.2024.155401_bib117","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6228982","article-title":"Knockdown of LINC01279 suppresses gastric cancer proliferation and migration by inhibiting PI3K\/Akt\/mTOR signaling pathway","volume":"2022","author":"Zhao","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib118","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ddr.21844","article-title":"PMEPA1 interference activates PTEN\/PI3K\/AKT, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitivity to gemcitabine and cisplatin","volume":"83","author":"Yang","year":"2022","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.prp.2024.155401_bib119","article-title":"NEIL3 mediates lung cancer progression and modulates PI3K\/AKT\/mTOR signaling: a potential therapeutic target","volume":"2022","author":"Huang","year":"2022","journal-title":"Int. J. Genom."},{"key":"10.1016\/j.prp.2024.155401_bib120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12905-022-02078-1","article-title":"Pentamidine inhibits proliferation, migration and invasion in endometrial cancer via the PI3K\/AKT signaling pathway","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Women's Health"},{"key":"10.1016\/j.prp.2024.155401_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1218467","article-title":"Artesunate, as an Hsp90 inhibitor, inhibits the proliferation of Burkitt\u2019s lymphoma cells by inhibiting AKT and ERK","volume":"14","author":"Yuan-Ce","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2024.155401_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110986","article-title":"Regulatory role of microRNAs on PTEN signaling","volume":"133","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2024.155401_bib123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clml.2019.03.017","article-title":"Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma","volume":"19","author":"Anwer","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.prp.2024.155401_bib124","doi-asserted-by":"crossref","first-page":"81926","DOI":"10.18632\/oncotarget.10745","article-title":"Kinase inhibitors as potential agents in the treatment of multiple myeloma","volume":"7","author":"Abramson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.1","article-title":"MEK inhibitors as a chemotherapeutic intervention in multiple myeloma","volume":"3","author":"Chang-Yew Leow","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.prp.2024.155401_bib126","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.3390\/cancers14194848","article-title":"Cytotoxic Mechanism of momilactones A and B against acute promyelocytic leukemia and multiple myeloma cell lines","volume":"14","author":"Anh","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib127","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/cancers11040435","article-title":"PTEN as a prognostic\/predictive biomarker in cancer: an unfulfilled promise?","volume":"11","author":"Bazzichetto","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib128","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.3390\/ijms21207539","article-title":"Role of microRNAs in diagnosis, prognosis and management of multiple myeloma","volume":"21","author":"Soliman","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib129","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ejca.2005.12.026","article-title":"Signalling and survival pathways in multiple myeloma","volume":"42","author":"Bommert","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1224138","article-title":"A spotlight on the interplay between Wnt\/\u03b2-catenin signaling and circular RNAs in hepatocellular carcinoma progression","volume":"13","author":"Mafi","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib131","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2174\/0929867330666230306143351","article-title":"New insights into the long non-coding RNAs dependent modulation of heart failure and cardiac hypertrophy: from molecular function to diagnosis and treatment","volume":"31","author":"Rezaee","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2024.155401_bib132","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prp.2024.155401_bib133","doi-asserted-by":"crossref","DOI":"10.2174\/0109298673259378231031061149","article-title":"Recent insights into the angioregulatory role of long non-coding RNAs and Circular RNAs in gliomas: from signaling pathways to clinical aspects","author":"Hedayati","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2024.155401_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175755","article-title":"Melatonin targeting non-coding RNAs in cancer: Focus on mechanisms and potential therapeutic targets","volume":"950","author":"Mafi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.prp.2024.155401_bib135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ejh.12124","article-title":"Aberrant micro RNA expression in multiple myeloma","volume":"91","author":"Dimopoulos","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib136","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/cancers11111738","article-title":"The role and function of microRNA in the pathogenesis of multiple myeloma","volume":"11","author":"Handa","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib137","doi-asserted-by":"crossref","DOI":"10.1111\/1440-1681.13768","article-title":"Exosomal miR-21-5p derived from multiple myeloma cells promote renal epithelial-mesenchymal transition through targeting TGF-\u03b2\/SMAD7 signaling pathway","author":"Liu","year":"2023","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.prp.2024.155401_bib138","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.18632\/oncotarget.14378","article-title":"EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions","volume":"8","author":"Alzrigat","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.663183","article-title":"Targeting c-Jun in A549 cancer cells exhibits antiangiogenic activity in vitro and in vivo through exosome\/miRNA-494-3p\/PTEN signal pathway","volume":"11","author":"Shao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib140","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.18632\/oncotarget.675","article-title":"DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma","volume":"3","author":"Amodio","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib141","doi-asserted-by":"crossref","first-page":"71292","DOI":"10.18632\/oncotarget.19772","article-title":"miR-708-5p: a microRNA with emerging roles in cancer","volume":"8","author":"Monteleone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib142","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.3390\/ijms232314765","article-title":"Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma","volume":"23","author":"Vlachov\u00e1","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib143","first-page":"2343","article-title":"Interaction of long-chain non-coding RNAs and important signaling pathways on human cancers","volume":"53","author":"Sun","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib144","first-page":"786","article-title":"Research progress on long-chain non-coding RNA in hepatocellular carcinoma","volume":"45","author":"Chen","year":"2020","journal-title":"Med. J. Chin. People'S. Lib. Army"},{"key":"10.1016\/j.prp.2024.155401_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112280","article-title":"Dysregulation of LncRNA ANRIL mediated by miR-411\u20133p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1\u03b1","volume":"396","author":"Wang","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.prp.2024.155401_bib146","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/genes6030484","article-title":"Molecular and cellular mechanisms of action of tumour suppressor GAS5 LncRNA","volume":"6","author":"Pickard","year":"2015","journal-title":"Genes"},{"key":"10.1016\/j.prp.2024.155401_bib147","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/cam4.5135","article-title":"Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta-analysis","volume":"12","author":"Qin","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.prp.2024.155401_bib148","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1111\/jcmm.14533","article-title":"Long non-coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation-dependent repression of CDH1 promoter","volume":"23","author":"Gao","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.prp.2024.155401_bib149","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","article-title":"LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prp.2024.155401_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175380","article-title":"Non-coding RNAs and exosomal ncRNAs in multiple myeloma: an emphasis on molecular pathways","author":"Hashemi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.prp.2024.155401_bib151","first-page":"1099","article-title":"LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204","volume":"6","author":"Li","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib152","first-page":"2561","article-title":"Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function","volume":"6","author":"Cao","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib153","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11928","article-title":"Circular RNAs are a large class of animal RNAs with regulatory potency","volume":"495","author":"Memczak","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.prp.2024.155401_bib154","doi-asserted-by":"crossref","first-page":"10667","DOI":"10.1007\/s11033-022-07668-8","article-title":"CircRNAs: novel therapeutic targets in multiple myeloma","volume":"49","author":"Zhou","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cell.2011.07.014","article-title":"A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?","volume":"146","author":"Salmena","year":"2011","journal-title":"cell"},{"key":"10.1016\/j.prp.2024.155401_bib156","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.prp.2024.155401_bib157","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/cr.2015.82","article-title":"Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis","volume":"25","author":"Li","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.prp.2024.155401_bib158","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of micro RNA therapeutics is coming of age","volume":"6","author":"Van Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.prp.2024.155401_bib159","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1261\/rna.844108","article-title":"miR-122 targeting with LNA\/2\u2032-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA\u2013peptide conjugates","volume":"14","author":"Fabani","year":"2008","journal-title":"Rna"},{"key":"10.1016\/j.prp.2024.155401_bib160","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.prp.2024.155401_bib161","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","article-title":"Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice","volume":"19","author":"Trang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2024.155401_bib162","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.prp.2024.155401_bib163","article-title":"Icaritin: a novel natural candidate for hematological malignancies therapy","volume":"2019","author":"Yang","year":"2019","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.prp.2024.155401_bib164","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/cells11060941","article-title":"Biological hallmarks and emerging strategies to target STAT3 signaling in multiple myeloma","volume":"11","author":"Zhou","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155401_bib165","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3892\/mmr.2016.4887","article-title":"Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K\/Akt\/mTOR signaling pathway","volume":"13","author":"Feng","year":"2016","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.prp.2024.155401_bib166","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2008.03.025","article-title":"Curcumin and cancer: an \u201cold-age\u201d disease with an \u201cage-old\u201d solution","volume":"267","author":"Anand","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155401_bib167","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2024.155401_bib168","doi-asserted-by":"crossref","DOI":"10.1177\/15347354231159322","article-title":"A review of the synergistic effects of curcumin with proteasome inhibitors in multiple myeloma preclinical models","volume":"22","author":"Pandya","year":"2023","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.prp.2024.155401_bib169","first-page":"3293","article-title":"Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines","volume":"25","author":"Ramachandran","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib170","first-page":"375","article-title":"Curcumin as adjuvant therapy to improve remission in myeloma patients: a pilot randomized clinical trial","volume":"13","author":"Santosa","year":"2022","journal-title":"Casp. J. Intern. Med."},{"key":"10.1016\/j.prp.2024.155401_bib171","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ejh.12870","article-title":"Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma","volume":"98","author":"de la Puente","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib172","article-title":"Downregulation of microRNA\u201125\u20113p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN\/PI3K\/AKT signaling pathway","volume":"47","author":"Zi","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.prp.2024.155401_bib173","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/cancers11091247","article-title":"Multifaceted regulation of PTEN subcellular distributions and biological functions","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib174","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/onc.2008.313","article-title":"PI3K\/Akt: getting it right matters","volume":"27","author":"Franke","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2024.155401_bib175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2024.155401_bib176","first-page":"2853","article-title":"The AKT kinase is activated in multiple myeloma tumor cells","volume":"98","author":"Hsu","year":"2001","journal-title":"Blood\u00a0J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib177","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrm3582","article-title":"Mechanisms and function of substrate recruitment by F-box proteins","volume":"14","author":"Skaar","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.prp.2024.155401_bib178","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155401_bib179","doi-asserted-by":"crossref","first-page":"9951","DOI":"10.18632\/aging.204432","article-title":"A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature","volume":"14","author":"Ji","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.prp.2024.155401_bib180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cell.2006.11.039","article-title":"NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN","volume":"128","author":"Wang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.prp.2024.155401_bib181","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.32615","article-title":"The NEDD4-1 E3 ubiquitin ligase: a potential molecular target for bortezomib sensitivity in multiple myeloma","volume":"146","author":"Huang","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib182","first-page":"3049","article-title":"Pathogenesis beyond the cancer clone (s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood\u00a0J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib183","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.prp.2024.155401_bib184","first-page":"1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood\u00a0J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib185","first-page":"5782","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood\u00a0J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib186","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/ijms20030702","article-title":"TRAF6 silencing attenuates multiple myeloma cell adhesion to bone marrow stromal cells","volume":"20","author":"Morgan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib187","first-page":"334","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood\u00a0J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib188","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/jcb.25159","article-title":"Oncogenic and therapeutic targeting of PTEN loss in bone malignancies","volume":"116","author":"Xi","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2024.155401_bib189","doi-asserted-by":"crossref","unstructured":"R.D. Harvey, S. Lonial, PI3 kinase\/AKT pathway as a therapeutic target in multiple myeloma. (2007).","DOI":"10.1007\/978-1-59745-564-0_20"},{"key":"10.1016\/j.prp.2024.155401_bib190","first-page":"1678","article-title":"The PI3K\/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib191","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib192","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2006.03.028","article-title":"The PTEN and INK4A\/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2024.155401_bib193","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.prp.2024.155401_bib194","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jpm12091428","article-title":"MiRNA as a Potential Target for Multiple Myeloma Therapy\u2013Current Knowledge and Perspectives","volume":"12","author":"Szudy-Szczyrek","year":"2022","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.prp.2024.155401_bib195","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-018-4845-0","article-title":"N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer","volume":"18","author":"Mrozik","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib196","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc2842","article-title":"Phosphoinositide signalling in cancer: beyond PI3K and PTEN","volume":"10","author":"Bunney","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib197","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib198","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib199","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.3390\/cancers14225613","article-title":"Targeting PTEN regulation by post translational modifications","volume":"14","author":"Gonz\u00e1lez-Garc\u00eda","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lfs.2015.12.031","article-title":"Melatonin, bone regulation and the ubiquitin-proteasome connection: a review","volume":"145","author":"Vriend","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2024.155401_bib201","doi-asserted-by":"crossref","first-page":"20563","DOI":"10.18632\/oncotarget.25003","article-title":"Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma","volume":"9","author":"Lamanuzzi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib202","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1080\/10428194.2017.1421760","article-title":"PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise","volume":"59","author":"Ramakrishnan","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.prp.2024.155401_bib203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155401_bib204","first-page":"2022007383","article-title":"AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity","author":"Bloedjes","year":"2022","journal-title":"Blood Adv., Bloodadvances"},{"key":"10.1016\/j.prp.2024.155401_bib205","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201658RR","article-title":"GSK-3\u03b2\/\u03b2-catenin pathway plays crucial roles in the regulation of NK cell cytotoxicity against myeloma cells","volume":"37","author":"Ren","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.prp.2024.155401_bib206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/biomedicines6020059","article-title":"The NF-\u03baB activating pathways in multiple myeloma","volume":"6","author":"Roy","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2024.155401_bib207","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3390\/ijms17122003","article-title":"Molecular mechanisms of p53 deregulation in cancer: an overview in multiple myeloma","volume":"17","author":"Herrero","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib208","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/jcm9061765","article-title":"Anti-VEGF drugs in the treatment of multiple myeloma patients","volume":"9","author":"Ria","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2024.155401_bib209","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/bjc.2012.527","article-title":"PDK1 inhibition is a novel therapeutic target in multiple myeloma","volume":"108","author":"Fujiwara","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib210","first-page":"2699","article-title":"Aurora kinase A is a target of Wnt\/\u03b2-catenin involved in multiple myeloma disease progression","volume":"114","author":"Dutta-Simmons","year":"2009","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib211","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/leu.2011.122","article-title":"The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma","volume":"25","author":"Martin","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib212","first-page":"539","article-title":"The role of miR-29b in cancer: regulation, function, and signaling","author":"Yan","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.prp.2024.155401_bib213","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00432-020-03127-8","article-title":"Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p\/SOX13 axis","volume":"146","author":"Liu","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib214","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2217\/bmm-2022-0349","article-title":"Role of ncRNA in multiple myeloma","volume":"16","author":"Leng","year":"2022","journal-title":"Biomark. Med."},{"key":"10.1016\/j.prp.2024.155401_bib215","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3390\/cancers14071700","article-title":"Circular RNA as a novel biomarker for diagnosis and prognosis and potential therapeutic targets in multiple myeloma","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib216","doi-asserted-by":"crossref","first-page":"86625","DOI":"10.18632\/oncotarget.21257","article-title":"Circular RNA expression profiles reveal that hsa_circ_0018289 is up-regulated in cervical cancer and promotes the tumorigenesis","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0771-7","article-title":"Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17\/miR-224 and regulating p21, PTEN expression","volume":"17","author":"Yang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib218","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","article-title":"Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growthantitumor activity of mir-21 inhibitors in multiple myeloma","volume":"19","author":"Leone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib219","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","article-title":"A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells","volume":"22","author":"Gull\u00e0","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14882","article-title":"Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma","volume":"179","author":"Handa","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib221","first-page":"1207","article-title":"Long noncoding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451","volume":"25","author":"Meng","year":"2017","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"10.1016\/j.prp.2024.155401_bib222","first-page":"3917","article-title":"Increased lncRNA HOTAIR expression promotes the chemoresistance of multiple myeloma to dexamethasone by regulating cell viability and apoptosis by mediating the JAK2\/STAT3 signaling pathway","volume":"20","author":"Guan","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib223","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13258-017-0518-7","article-title":"MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy","volume":"39","author":"Bong","year":"2017","journal-title":"Genes Genom."},{"key":"10.1016\/j.prp.2024.155401_bib224","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000492846","article-title":"Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate HOXA11 expression by sponging miR-181a in multiple myeloma","volume":"49","author":"Shen","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.prp.2024.155401_bib225","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","article-title":"Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidenceantitumor activity of miR-34a in multiple myeloma","volume":"18","author":"Di Martino","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib226","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.2174\/0929867321666140601204513","article-title":"Targeting the phosphatidylinositol 3-kinase\/AKT pathway for the treatment of multiple myeloma","volume":"21","author":"Zhu","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2024.155401_bib227","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1021\/jm9002395","article-title":"Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2024.155401_bib228","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1940-6207.CAPR-11-0397","article-title":"Taxifolin suppresses UV-induced Skin carcinogenesis by targeting EGFR and PI3KTaxifolin suppresses UV-induced skin carcinogenesis","volume":"5","author":"Oi","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.prp.2024.155401_bib229","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/biom12111647","article-title":"Synergistically anti-multiple myeloma effects: flavonoid, non-flavonoid polyphenols, and bortezomib","volume":"12","author":"Ding","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.prp.2024.155401_bib230","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5560915","article-title":"Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme","volume":"2021","author":"Yao","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib231","first-page":"3239","article-title":"Plant flavonoid taxifolin inhibits the growth, migration and invasion of human osteosarcoma cells","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib232","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1039\/D0QO00785D","article-title":"The present and future synthetic strategies of structural modifications of sinomenine","volume":"7","author":"Ng","year":"2020","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.prp.2024.155401_bib233","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.tranon.2018.08.014","article-title":"Autophagy: a new mechanism of prosurvival and drug resistance in multiple myeloma","volume":"11","author":"Desantis","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib234","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.3390\/ijms23116075","article-title":"The potential of epigallocatechin gallate (EGCG) in targeting autophagy for cancer treatment: a narrative review","volume":"23","author":"Ferrari","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155401_bib235","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nutres.2022.05.003","article-title":"Naringenin induces intrinsic and extrinsic apoptotic signaling pathways in cancer cells: a systematic review and meta-analysis of in vitro and in vivo data","volume":"105","author":"Faramarzi","year":"2022","journal-title":"Nutr. Res."},{"key":"10.1016\/j.prp.2024.155401_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.inoche.2023.111989","article-title":"Green tea-mediated synthesis of silver nanoparticles: Enhanced anti-cancer activity and reduced cytotoxicity melanoma and normal murine cell lines","volume":"161","author":"Golpour","year":"2024","journal-title":"Inorg. Chem. Commun."},{"key":"10.1016\/j.prp.2024.155401_bib237","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00011-022-01599-7","article-title":"The effect of immunomodulatory properties of naringenin on the inhibition of inflammation and oxidative stress in autoimmune disease models: a systematic review and meta-analysis of preclinical evidence","volume":"71","author":"Alimohammadi","year":"2022","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.prp.2024.155401_bib238","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10787-022-00994-0","article-title":"The effects of apigenin administration on the inhibition of inflammatory responses and oxidative stress in the lung injury models: a systematic review and meta-analysis of preclinical evidence","volume":"30","author":"Rahimi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.prp.2024.155401_bib239","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/fsn3.3217","article-title":"Natural antioxidants from some fruits, seeds, foods, natural products, and associated health benefits: an update","volume":"11","author":"Rahaman","year":"2023","journal-title":"Food Sci. Nutr."},{"key":"10.1016\/j.prp.2024.155401_bib240","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/13880209.2019.1662814","article-title":"2, 4-Dihydroxy-3\u2032-methoxy-4\u2032-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K\/akt\/mTOR signaling pathway","volume":"57","author":"Zhu","year":"2019","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.prp.2024.155401_bib241","first-page":"1117","article-title":"Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-\u03baB pathway","volume":"39","author":"Tozawa","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib242","first-page":"489","article-title":"Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k\/Akt\/NF-\u03baB pathways in human multiple myeloma cells","volume":"22","author":"Yang","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.prp.2024.155401_bib243","article-title":"Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2024.155401_bib244","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12944-017-0489-3","article-title":"Punicic acid: a striking health substance to combat metabolic syndromes in humans","volume":"16","author":"Shabbir","year":"2017","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.prp.2024.155401_bib245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phrs.2018.04.021","article-title":"Possible use of Punica granatum (Pomegranate) in cancer therapy","volume":"133","author":"Khwairakpam","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2024.155401_bib246","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.prp.2024.155401_bib247","series-title":"Seminars in Cancer Biology vol. 85","first-page":"69","author":"Yu","year":"2022"},{"key":"10.1016\/j.prp.2024.155401_bib248","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 Is a Novel Dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155401_bib249","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155401_bib250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbior.2015.05.001","article-title":"Implication of PI3K\/Akt pathway in pancreatic cancer: when PI3K isoforms matter?","volume":"59","author":"Baer","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.prp.2024.155401_bib251","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2024.155401_bib252","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.prp.2024.155401_bib253","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/cancers9040029","article-title":"The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma","volume":"9","author":"Piddock","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155401_bib254","first-page":"1460","article-title":"PI3K\/p110\u03b4 is a novel therapeutic target in multiple myeloma","volume":"116","author":"Ikeda","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib255","first-page":"1092","article-title":"Inhibitory effect of LY294002 on proliferation of multiple myeloma cells and its mechanism","volume":"25","author":"Wang","year":"2017","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"10.1016\/j.prp.2024.155401_bib256","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.12734","article-title":"PI 3 KCA plays a major role in multiple myeloma and its inhibition with BYL 719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance","volume":"165","author":"Azab","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib257","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00277-018-3547-7","article-title":"Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation","volume":"98","author":"Okabe","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib258","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib259","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41420-018-0060-7","article-title":"NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin","volume":"4","author":"Hsu","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.prp.2024.155401_bib260","first-page":"87","article-title":"NVP-BEZ235-induced autophagy as a potential therapeutic approach for multiple myeloma","volume":"11","author":"Ma","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.prp.2024.155401_bib261","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11912-007-0040-1","article-title":"Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor","volume":"9","author":"George","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib262","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13277-010-0016-x","article-title":"Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K\/AKT signaling","volume":"31","author":"Sun","year":"2010","journal-title":"Tumor Biol."},{"key":"10.1016\/j.prp.2024.155401_bib263","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-15-1076","article-title":"A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1\/2 Inhibitor, in Relapsed\/Refractory Multiple MyelomaA Phase II Study of AZD6244 in Multiple Myeloma","volume":"22","author":"Holkova","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib264","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","article-title":"MLN120B, a novel I\u03baB kinase \u03b2 inhibitor, blocks multiple myeloma cell growth in vitro and in vivo","volume":"12","author":"Hideshima","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155401_bib265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114992","article-title":"Toll-like receptors: new targets for multiple myeloma treatment?","author":"Akesolo","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.prp.2024.155401_bib266","unstructured":"P.M. Voorhees et al. (American Society of Hematology Washington, DC, 2013)."},{"key":"10.1016\/j.prp.2024.155401_bib267","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.prp.2024.155401_bib268","series-title":"Seminars in Oncology","author":"Pan","year":"2023"},{"key":"10.1016\/j.prp.2024.155401_bib269","first-page":"1","article-title":"The Impact of Panobinostat on Cell Death in Combination with S63845 in Multiple Myeloma Cells","author":"Tagoug","year":"2023","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.prp.2024.155401_bib270","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"science"},{"key":"10.1016\/j.prp.2024.155401_bib271","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.prp.2024.155401_bib272","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2014.03.035","article-title":"Hif-1\u03b1 and Hif-2\u03b1 differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells","volume":"349","author":"Hu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155401_bib273","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.prp.2024.155401_bib274","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108502","article-title":"IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38\/NF-\u03baB signal pathway","volume":"9","author":"Feng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2024.155401_bib275","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/fon.10.2","article-title":"Novel therapeutic targets for multiple myeloma","volume":"6","author":"Mahindra","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib276","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","article-title":"Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments","volume":"414","author":"Hu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155401_bib277","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcyt.2018.10.006","article-title":"Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA\/BCL-2 expression","volume":"21","author":"Deng","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.prp.2024.155401_bib278","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.155","article-title":"Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy","volume":"5","author":"Gallo","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prp.2024.155401_bib279","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: Potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2024.155401_bib280","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2019.1615051","article-title":"A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma","volume":"18","author":"Cengiz Seval","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.prp.2024.155401_bib281","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.prp.2024.155401_bib282","first-page":"1057","article-title":"Efficacy and toxicity of histone deacetylase inhibitors in relapsed\/refractory multiple myeloma: systematic review and meta\u2011analysis of clinical trials","volume":"18","author":"Gao","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.prp.2024.155401_bib283","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279716","article-title":"Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way","author":"Giannandrea","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2024.155401_bib284","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.3390\/cells10113185","article-title":"Role of extracellular vesicle-based cell-to-cell communication in multiple myeloma progression","volume":"10","author":"Saltarella","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155401_bib285","doi-asserted-by":"crossref","first-page":"36151","DOI":"10.18632\/oncotarget.26319","article-title":"Human liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt\/mTOR\/PTEN combined modulation","volume":"9","author":"Fonsato","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155401_bib286","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Ror\u00e0","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib287","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/neuonc\/nox128","article-title":"Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma","volume":"20","author":"Wu","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.prp.2024.155401_bib288","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib289","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1038\/sj.onc.1208118","article-title":"p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells","volume":"23","author":"Hideshima","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2024.155401_bib290","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3892\/ijo.2017.4171","article-title":"SRC3 expressed in BMSCs promotes growth and migration of multiple myeloma cells by regulating the expression of Cx43","volume":"51","author":"Jin","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib291","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5114\/aoms.2017.64722","article-title":"Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance","author":"Fu","year":"2017","journal-title":"Arch. Med. Sci. 13"},{"key":"10.1016\/j.prp.2024.155401_bib292","first-page":"805","article-title":"Effect of TRIM31 gene silencing on the proliferation and apoptosis of U266 cells and its mechanism","volume":"29","author":"Long","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.prp.2024.155401_bib293","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20194334","article-title":"TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt\/\u03b2-catenin signaling","volume":"40","author":"Xiao","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.prp.2024.155401_bib294","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/biomedicines10020307","article-title":"Enhanced chimeric antigen receptor T cell therapy through co-application of synergistic combination partners","volume":"10","author":"Stock","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2024.155401_bib295","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.prp.2024.155401_bib296","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2024.155401_bib297","first-page":"523","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood\u00a0J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib298","article-title":"Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D (bbz) CAR-T cells","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib299","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2024.155401_bib300","first-page":"41","article-title":"Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients","volume":"12","author":"Dadacaridou","year":"2007","journal-title":"J. Buon"},{"key":"10.1016\/j.prp.2024.155401_bib301","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/biomedicines10051001","article-title":"Looking for the Holy Grail\u2014drug candidates for glioblastoma multiforme chemotherapy","volume":"10","author":"Paj\u0105k","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2024.155401_bib302","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.prp.2024.155401_bib303","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1080\/10428194.2017.1421760","article-title":"PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise","volume":"59","author":"Ramakrishnan","year":"2018","journal-title":"Leuk. Lymphoma"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824003121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824003121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T19:21:48Z","timestamp":1735154508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824003121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":303,"alternative-id":["S0344033824003121"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155401","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of the PTEN\/PI3K\/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155401"}}